Tuesday, October 4, 2022

561.316.3330

Biotechnology News Magazine

TransCode Therapeutics Announces Expansion of Global RNA Oncology Patent Portfolio

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today announced extension of its intellectual property portfolio through the filing of a provisional patent application (US 63/356,449) entitled RADIOLABELED NANOPARTICLES AND TEMPLATE DIRECTED IMMUNOMODULATION FOR CANCER THERAPY (the ‘449 application). TransCode expects to convert the ‘449 application into an international application in approximately one year.

The ‘449 application is directed at introducing radiotherapy into the delivery of nanoparticles carrying RNA-based agonist precursors of pattern recognition receptors (PRR). Radiotherapy can be deployed for use in cancer in either a systemic or focused manner, potentially inducing tumor cells to release tumor-derived neoantigens along with activation of the RIG-I signaling pathway. Once inside a tumor cell, as described in the ‘449 application and in TransCode’s preclinical testing, the nanoparticle carrying the selected PRR-activating oligonucleotide encounters a microRNA specific to that tumor, activating a type I interferon-driven immune response. The resulting immune response combined with tumor-derived antigens from the radiation may have the potential to reengage the patient’s immune system and deliver synergistic therapeutic efficacy.

TransCode’s CEO, Michael Dudley, said, “We believe that by combining radiotherapy with RIG-I activation, this technology could become an important approach to how we potentially treat cancer. Activating the RIG-I mechanism has the potential of building immunological memory and giving patients’ immune systems the ability to reject tumors as though they were foreign bodies.”

The filing of the ‘449 application supports TransCode’s goals of deploying the right therapy for individual cancer patients. TransCode’s intellectual property portfolio comprises several patent families representing issued patents, pending patent applications and new provisional patent applications. If issued, the proposed patent would join a number of other granted patents TransCode owns or licenses, including US 9,629,812 and EP 2 961 386. As part of its overall patent strategy, TransCode pursues intellectual property protection for additional components of its discovery engine built around its TTX delivery platform. The TTX platform consists of a hemodynamic and metabolic tumor targeting delivery system designed to enable deployment of a variety of RNA therapeutic candidates including RNAi, pattern recognition receptors, messenger RNA, gene repair/replacement and radiolabeled therapeutics.

Dudley added, “While we are focused on advancing TTX-MC138, our lead therapeutic candidate targeting microRNA-10b, into first-in-human studies, we are excited by our platform’s potential to be used more broadly in a variety of RNA approaches targeting genes responsible for cancer. The approach represented by the ’449 application filing, if successful in development, could expand our ability to deploy multimodal therapy for individual patients based on the versatility our platform offers.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine